2024-03-22 15:27:11 ET
Summary
- The global market size for personalized medicines is estimated to reach $1,233.23 billion by 2033, with North America experiencing significant growth in the oncology sector.
- Natera Inc., a diagnostic company, focuses on women's health, oncology, and organ health, with major revenue drivers including non-invasive prenatal tests and personalized molecular residual disease tests.
- Natera reported a 43% year-on-year increase in revenue in Q4 2023, with a goal to achieve cash flow break even by Q3 2024 or sooner.
Read the full article on Seeking Alpha
For further details see:
Natera: Capitalizing On The Positive Momentum Of Personalized Medicine